We give doctors access to a variety of sequencing capabilities, all with full transcriptome and tumor/normal match. We partner with physicians and hospitals to augment a hospital's current offering by providing access to Next Generation Sequencing with cutting-edge analytics and an interactive machine learning platform that also leverages data across our platform.
Targeted Panel of 648 genes
Enriched for clinically relevant genes and genes of emerging clinical relevanceLearn more
Whole Exome of ~20,000 genes
Providing the broadest genomic coverage for analysisDownload validation summary
Targeted Panel of 105 genes
Designed to detect actionable oncological targets in plasmaLearn more
Targeted panel of 15 genes
Whole exome architectureLearn more
Capable of analyzing and reporting on individual genes with clinical significance for specific cancer subtypes.
DNA sequencing using tumor/normal match
Utilizing our proprietary xT and xE assays, we perform a tumor/normal matched analysis by sequencing both a tumor DNA sample and a normal DNA sample (blood or saliva) to ensure that your report accurately distinguishes between your patient’s somatic and germline variants.
Utilizing our proprietary RNA extraction protocols, we perform high-quality RNA sequencing on all samples we sequence through our xT and xE panels, where specimen quality and quantity allow. Profiling of the whole RNA transcriptome provides molecular information that is complementary to DNA sequencing and can be clinically important. This allows for clinically validated unbiased translocation detection.
Auto-conversion option to liquid biopsy
Through a simple automatic conversion selection, a biopsy-based Tempus|xT test can be converted to a blood-based Tempus|xF test in the event of an insufficient tumor tissue sample.
The tempus SEQUENCING lab
We've built a state-of-the-art, CAP-accredited and CLIA-certified lab. Our highly robotic laboratory is optimized for high-throughput clinical next-generation sequencing with a current capacity of over 100,000 patients annually. Sequencing is completed within two to three weeks of receiving patient samples.Download our lab overview
AS PUBLISHED IN NATURE BIOTECHNOLOGY JOURNAL
“Extensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials […] and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing.”Learn more about the xT 500 Publication in Nature Biotechnology
Combined DNA and RNA sequencing using Tempus|xT increased the high level therapy matching rate to 43.4% of patients.
Follow-Up Testing Covered Under Tempus Financial Assistance*
Any patients who receive Tempus testing may apply for Tempus’ Financial Assistance Program. If approved, the Program covers all Tempus|xF (liquid) or Tempus|xT (solid) testing within 18 months of Program approval. All U.S.-based patients may qualify.* Tempus testing is always conducted based on the medical judgement of an ordering physician.
Targeted panel of 648 genes
Targeted panel enriched for clinically relevant genes and most commonly mutated cancer driver genes with additional genes of emerging clinical significance focused on immediately actionable mutations.
Targeted panel of 105 genes
Targeted panel designed to detect actionable oncological targets in plasma.
Targeted panel of 15 genes
The Tempus|xG Neurology & Psychiatry test reports on the following 15 genes.